—
C+
C+ The full Closelook — membership. Open the C+ overview

Almirall S.A. (ALM.MC) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Almirall S.A.

ALM.MC in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Almirall develops medicines for skin conditions such as psoriasis, atopic dermatitis, acne and actinic keratosis, alongside products in several other therapeutic areas. It runs a pipeline of experimental compounds at different trial stages, often working with outside research partners on early-stage science. The company is headquartered in Barcelona, Spain, and trades on the Madrid exchange.
Where it sits in the stack
Almirall carries no seat in our index; it sits in the specialty pharmaceutical sleeve of our universe, outside the AI build-out stack the diary otherwise tracks.
Who it is priced against
The wider market groups it with other skin-focused biopharmaceutical firms; a name often mentioned alongside it is Galderma.
Why Closelook tracks it
Almirall holds no seat in our index and carries no Closelook score; the diary has not yet built coverage for it.
What the diary watches
Whether the dermatology pipeline, including compounds still in early and mid-stage trials, advances and changes how the skin-health portfolio is read.

Almirall S.A. (ALM.MC) trades on the MC exchange in Spain, classified under Healthcare.

The Closelook company score reads 52/100 composite (momentum 25, quality 44, valuation 67) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for ALM.MC, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - Specialty & Generic · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against ALM.MC on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 1.43%, annual · last 0.15 EUR on 2026-05-14

Dividends and capital return

What ALM.MC pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.15 EUR per share · a 1.43% yield on the 2026-09-17 close 1 distribution, paid once a year 2026-09-17
  • Change on the year +1.7% against the prior twelve months prior twelve months 0.15 EUR per share
  • Last distribution 0.15 EUR per share as the price series records it, within days of the ex-date 2026-05-14
  • By calendar year 2025: 0.15 EUR (partial) · 2026: 0.15 EUR to date first distribution recorded in the three-year window: 2025-05-15
  • Dividends paid, FY2025 26 m EUR 83% of earnings
  • Share count +1.6% in FY2025
  • Capital returned 26 m EUR · 20% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sector × region Health care in Europe: +1.1% week · −3.6% month · +0.3% quarter · −6.5% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-16
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Almirall S.A. (ALM.MC)?

Almirall S.A. trades as ALM.MC on the MC exchange (Spain) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-18.

Is ALM.MC in a Closelook index?

Not currently — Almirall S.A. is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

What is Almirall S.A.'s Closelook composite score?

52 out of 100, with momentum 25, quality 44 and valuation 67 sub-scores, as of 2026-09-18. Scores are Closelook's own research readings, not ratings or investment advice.

Where does ALM.MC trade against its moving averages?

Downtrend stack: Trades -0.7% vs the 50-day and -10.1% vs the 200-day average, 23.2% below the 52-week high and +5.8% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Almirall S.A. do?

Almirall develops medicines for skin conditions such as psoriasis, atopic dermatitis, acne and actinic keratosis, alongside products in several other therapeutic areas. It runs a pipeline of experimental compounds at different trial stages, often working with outside research partners on early-stage science. The company is headquartered in Barcelona, Spain, and trades on the Madrid exchange. The wider market groups it with other skin-focused biopharmaceutical firms; a name often mentioned alongside it is Galderma.

Where does Almirall S.A. sit in the AI build-out?

Almirall carries no seat in our index; it sits in the specialty pharmaceutical sleeve of our universe, outside the AI build-out stack the diary otherwise tracks. Almirall holds no seat in our index and carries no Closelook score; the diary has not yet built coverage for it.

Does Almirall S.A. pay a dividend?

Almirall S.A. has paid 0.15 EUR per share over the last twelve months, paid once a year, a trailing yield of 1.43% on the 2026-09-17 close; the last distribution recorded in the price series was 0.15 EUR on 2026-05-14. In fiscal 2025 the company paid 26 m EUR in dividends, 20% of that year’s free cash flow. The share count rose 1.6% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for ALM.MC, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.